25mg Flush Niacin (start here!!!): https://t.co/KlQKHbLj0B 500mg Flush Niacin (advanced users): https://t.co/rnW84C0kTk REFERENCE: Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1 https://t.co/2zkfslQX9F
Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1.
Mentions
Extended reach
Total likes
Video views
Mentions per month
May 2025 – Oct 2025Where it's discussed
-
X / Twitter7 posts
-
News6 articles
-
Blogs4 articles
-
YouTube3 videos
AI synopsis
What people are saying
Discussions highlight the potential for niacin to modulate miR-93 levels, with users describing the findings as promising for future therapies, using words like 'important', 'game changer', and 'potential breakthrough', which reflect both high interest and perceived impact. The tone suggests a recognition of the research's significance in advancing understanding and treatment options for liver disease.
Most discussions acknowledge the significance of the research, with many expressing support or agreement with the findings about miR-93's role in liver disease.
Posts show high interest, with users emphasizing potential treatments like niacin and discussing implications for future therapies.
Many users engage deeply by sharing thoughts on the mechanisms involved and potential impact, indicating moderate to high engagement levels.
The discussions hint at notable impact, with some posts suggesting this research could influence treatment approaches for MASLD.
Abstract in brief
- The study shows that miR93 is significantly increased in the liver tissues of patients with MASLD and obese mice, and that knocking out miR93 reduces liver fat accumulation by increasing SIRT1 levels and promoting fatty acid breakdown.
- miR93 directly targets SIRT1, a gene involved in regulating metabolism, and reducing miR93 boosts SIRT1 activity, which helps protect the liver from fat buildup through the LKB1-AMPK pathway.
- The research suggests that treatments like niacin can lower miR93 levels, thereby enhancing SIRT1 function and potentially offering a new therapy for MASLD, a disease with limited current treatment options.]
Top posts
Most liked on X and Blueskyhttps://t.co/zIX3n5uEcU
Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1 https://t.co/irHgIhRDxF
"مفاجأة من العيار الثقيل: أخيرًا اكتشاف فيتامين يقضي على الكبد الدهني وي... https://t.co/oAWmKtUlrk via @YouTube
"مفاجأة من العيار الثقيل: أخيرًا اكتشاف فيتامين يقضي على الكبد الدهني وي... https://t.co/8n9cuMJS5v عبر @YouTube
https://t.co/mtCVZYhPX5
All mentions
Role of miR93 and SIRT1 in Metabolic Liver Disease Pathogenesis
The study shows that miR93 is significantly increased in liver tissues of MASLD patients and obese mice, with knocking out miR93 reducing liver fat accumulation by increasing SIRT1 levels and promoting fatty acid…
Role of miR93 in MASLD Development and Potential Therapeutic Targets
miR93 is significantly increased in MASLD, promoting liver fat accumulation by suppressing SIRT1. Reducing miR93 enhances SIRT1 activity, aiding fat breakdown. Treatments like niacin may lower miR93 levels, offering new…
Natural Treatment for Fatty Liver Disease Using Niacin and miR93 Regulation
This video explores groundbreaking research indicating that niacin, a common supplement, can lower miR93 levels and increase SIRT1 activity, potentially reversing fatty liver disease by promoting fat breakdown and…
"مفاجأة من العيار الثقيل: أخيرًا اكتشاف فيتامين يقضي على الكبد الدهني وي... https://t.co/oAWmKtUlrk via @YouTube
https://t.co/mtCVZYhPX5
"مفاجأة من العيار الثقيل: أخيرًا اكتشاف فيتامين يقضي على الكبد الدهني وي... https://t.co/8n9cuMJS5v عبر @YouTube
https://t.co/zIX3n5uEcU
https://t.co/feZFU3KjCi
25mg Flush Niacin (start here!!!): https://t.co/KlQKHbLj0B 500mg Flush Niacin (advanced users): https://t.co/rnW84C0kTk REFERENCE: Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1 https://t.co/2zkfslQX9F
Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1 https://t.co/irHgIhRDxF